Skip to content

Palvella Therapeutics PVLA Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$16K+77.8%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.86B+468%

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
Palvella Therapeutics (PVLA) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of $8K in Q1 2026.
How has Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax changed year-over-year?
Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax increased by 233.3% year-over-year, from -$6K to $8K.
What does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax mean?
This represents the net gains or losses resulting from translating the financial statements of foreign subsidiaries into the company's reporting currency. It captures the impact of exchange rate fluctuations on the value of international assets and liabilities. This metric helps investors isolate the effects of currency volatility from core operational performance.